Investment Rating - The report maintains a "Buy" rating for WuXi Biologics (2269.HK) [2] Core Insights - WuXi Biologics achieved a revenue of 21.79 billion RMB in 2025, representing a year-over-year growth of 16.7%. The company also reported an IFRS gross profit of 10.02 billion RMB, up 30.9% year-over-year, and an adjusted net profit of 6.59 billion RMB, reflecting a 22.0% increase [7] - The company has a strong order backlog, with total unfulfilled orders reaching 23.7 billion USD by the end of 2025, indicating solid revenue prospects for the future [7] - The three main business segments of the company are performing well, with significant contributions from preclinical projects and late-stage clinical/commercial projects [7] Financial Forecasts - Revenue projections for WuXi Biologics are as follows: - 2025: 21.79 billion RMB - 2026: 25.42 billion RMB - 2027: 29.66 billion RMB - 2028: 34.51 billion RMB - The expected growth rates for revenue are approximately 16.7% for 2026 and 16.6% for 2027 [2] - The net profit attributable to shareholders is forecasted to grow from 4.91 billion RMB in 2025 to 8.02 billion RMB by 2028, with a growth rate of 46.3% in 2025 [2] Business Segments Performance - The preclinical segment generated revenue of 9.31 billion RMB in 2025, up 31.9% year-over-year, while the late-stage clinical and commercial projects brought in 9.46 billion RMB, a 26.4% increase [7] - The company has signed 209 new projects in 2025, with 156 IND submissions completed, showcasing its operational efficiency [7] - The commercial production capacity is expected to ramp up significantly, with over 10 platform projects projected to have peak sales potential exceeding 5 billion USD [7]